Please login to the form below

Not currently logged in
Email:
Password:

Award for Patient-Centricity

Sponsored by

Back to Results


Highly Commended

NINLARO Patient Support Programme

by Takeda UK and Ireland with support from Apodi Limited


Summary of work

Takeda and Apodi have developed and deployed a Support Programme for Patients prescribed NINLARO which is fully aligned with Takeda’s core values and Apodi’s model for patient-centricity

The programme is delivered by experienced NINLARO Specialist Nurses (NSNs), who provide incremental and integrated capacity to NHS units, and deliver high levels of quality patient interactions which can take place in clinic, on the telephone, in the patient’s home, or any combination of these.

At participating hospitals, every NINLARO patient has a named NSN, together with a tailored support plan aligned with their preferences. This drives continuity of care, the best possible experiences and outcomes and helps them, and their Healthcare Professionals (HCPs) to identify and manage toxicities early, thus driving appropriate time on therapy.

The PSP is supported by educational literature for both patients and HCPs which is designed to drive knowledge and confidence in treatment and management.

Feedback from both patients and HCPs demonstrates that the programme is having positive effects on treatment outcomes and is highly valued.

The Programme at each Trust is reviewed regularly by Senior Management at Takeda, Apodi and the Trust to ensure high levels of performance and a culture of continuous improvement.

Judges' comments

This entry from Takeda and Apodi was quite simply phenomenal! It is a fabulous patient support programme with good insight, clear and well measured objectives and successful outcomes.


Winner

Community Mental Health Project - by Attigo CIC, with support from Johnson and Johnson, The Department for International Development and Yale University


Highly commended

NINLARO Patient Support Programme - by Takeda UK and Ireland with support from Apodi Limited


Finalists

The APPEAL Study: Uncovering Psychosocial Burden in Peanut Allergy - by Aimmune Therapeutics with support from Solaris Health, Acaster Lloyd Consulting and Brainsell

RAREfest - by Cambridge Rare Disease Network with support from Havas Life Medicom

GLAD I Took Part - by King’s College London with support from Four Health


Key dates

Entry deadline 27 August 2020
Extended entry deadline 3 September 2020*
*additional fee applies
Judging Day 1 October 2020
Company of the Year Interviews 22 October 2020
PMEA Event 25 November 2020